pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
BOEHRINGER INGELHEIM · news · pharmadog
← back to BOEHRINGER INGELHEIM
News mentioning BOEHRINGER INGELHEIM
79
stories
1d
Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
biospace
3d
Their loss, our gain? Canada makes its case to Europe amid U.S. instability
biospace
6d
Gubra CEO gets the quick hook; Ex-HHS official Brett Giroir takes over at cancer biotech
endpoints
8d
Drug price hikes in Germany could push US costs higher, study says
biopharma dive
8d
Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
biospace
9d
Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorder
biospace
10d
FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
biospace
10d
Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage test
biospace
10d
#AHA26: Boehringer to seek approval of obesity shot, but gaining market share could be tricky
endpoints
13d
Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
biopharma dive
13d
AHA: Boehringer aims for 2027 survodutide submission after obesity drug passes cardio test
fiercebiotech
14d
MetaVia sees GLP-1 shed liver fat and body weight in phase 1, takes aim at specific liver disease
fiercebiotech
15d
Boehringer bets big on China, offering $7B biobucks for Sino cancer programs
biospace
15d
STAT+: Ultragenyx cuts staff after another study fails
stat
15d
Boehringer Ingelheim strikes $7B backloaded ADC, TCE cancer deal with China's Sino
endpoints
15d
Boehringer returns to Sino Biopharma in $7.4B deal for preclinical TCEs, ADCs
fiercebiotech
24d
Boehringer, Microsoft team up to explore digital patient twins for clinical trials
fiercebiotech
27d
Roche flags ‘final opportunity’ for Germany to reestablish as a reliable investment location
biospace
27d
STAT+: Pharmalittle: We’re reading about a cancer vaccine, an experimental pancreatic cancer drug, and more
stat
27d
Roche pays Zymeworks $55M for trispecific challenger to Amgen’s Imdelltra
fiercebiotech
28d
A hepatitis B hold lifted and drug tabled; Ultomiris' accelerated approval
endpoints
28d
ESMO: Boehringer builds case for late-phase rival to Amgen’s Imdelltra
fiercebiotech
Oct 14, 26
Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugs
biospace
Oct 14, 26
Zealand inks $1.2B Generate pact to add multispecific proteins to obesity pipeline
fiercebiotech
Oct 8, 26
Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbers
biospace
Oct 8, 26
Endeavor’s threat to IPF incumbents increases after phase 2 win for Hedgehog inhibitor
fiercebiotech
Oct 7, 26
Matchpoint nets $150M series B to take covalent med into clinic
fiercebiotech
Oct 6, 26
BioSpace 40 Under 40 winners make their mark on biopharma
biospace
Oct 2, 26
STAT+: Pharmalittle: We’re reading about the 340B drug pilot program, an obesity drug disappointment, and more
stat
Oct 1, 26
3 takeaways from a European obesity scientific meeting
biopharma dive
← prev
page 1 of 3
next →